Hubei Jumpcan Pharmaceutical Stock Target Price
| 600566 Stock | 29.02 0.12 0.42% |
Hubei Jumpcan Pharmaceutical fundamentals help investors to digest information that contributes to Hubei Jumpcan's financial success or failures. It also enables traders to predict the movement of Hubei Stock. The fundamental analysis module provides a way to measure Hubei Jumpcan's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hubei Jumpcan stock.
Hubei | Target Price |
Hubei Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hubei Jumpcan's direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hubei Jumpcan could also be used in its relative valuation, which is a method of valuing Hubei Jumpcan by comparing valuation metrics of similar companies.Hubei Jumpcan is currently under evaluation in target price category among its peers.
Hubei Fundamentals
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.0978 | ||||
| Profit Margin | 0.31 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 16.23 B | ||||
| Shares Outstanding | 921.7 M | ||||
| Shares Owned By Insiders | 62.47 % | ||||
| Shares Owned By Institutions | 8.79 % | ||||
| Price To Book | 1.90 X | ||||
| Price To Sales | 2.97 X | ||||
| Revenue | 9.65 B | ||||
| Gross Profit | 7.46 B | ||||
| EBITDA | 3.01 B | ||||
| Net Income | 2.82 B | ||||
| Total Debt | 1.04 B | ||||
| Book Value Per Share | 15.37 X | ||||
| Cash Flow From Operations | 3.46 B | ||||
| Earnings Per Share | 3.03 X | ||||
| Target Price | 52.36 | ||||
| Number Of Employees | 5.23 K | ||||
| Beta | 0.2 | ||||
| Market Capitalization | 26.46 B | ||||
| Total Asset | 18.14 B | ||||
| Retained Earnings | 8.85 B | ||||
| Working Capital | 9.64 B | ||||
| Net Asset | 18.14 B | ||||
| Last Dividend Paid | 1.3 |
About Hubei Jumpcan Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hubei Jumpcan Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hubei Jumpcan using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hubei Jumpcan Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Hubei Stock
Hubei Jumpcan financial ratios help investors to determine whether Hubei Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hubei with respect to the benefits of owning Hubei Jumpcan security.